Shanghai-based VelaVigo has been busy. The biotech granted Avenzo Therapeutics ex-China rights to a Nectin4xTROP2 bispecific antibody-drug conjugate in November, netting up to $50 million in ...

So, here we are, launching our fourth edition of Fierce Biotech's layoff tracker. As always, if you know of a layoff occurring at a biotech, please reach out to the Fierce Biotech editorial team ...

Biotech stocks are in the eye of the storm as the world recovers from the global pandemic. Government institutions and professional traders are banking on biotech stocks to continually develop a ...

Celebrating 10 years, we are a Boston-based change management and strategy consultant firm working… Boston, MA – VPNE Parking Solutions, LLC, a leader in the parking, transportation, hospitali ...

half-day interactive event designed to equip… The Future of Bay Area Biotech: Searching For Answers Join the San Francisco Business Times for our annual 40 Under 40 awards event celebrating ...

Mark Warner, D-Va., during discussions Wednesday. “In Roanoke, I think we’re one big deal away from the incredible biotech community that is nascent here kind of breaking through to the big ...

The biotech industry experienced heady highs in early 2021, but has since suffered from a tight financial climate that has brought bankruptcies and widespread redundancies. Ben Hargreaves examines ...

The Chinese biotech industry has grown rapidly to become a major hub of research. However, as US-China trade relations continue to deteriorate, Ben Hargreaves asks whether this could stunt ...

The 2025 STATUS List features 50 influential people shaping the future of health and life sciences across biotech, medicine, health care, policy, and health tech. The list is wide-ranging ...

wallpaper, and education, as well as consumer office, stationery and craft papers to retailers, small business, personal use, and educational applications; and healthcare and other products ...

Jonathan Faison, Head of the ROTY Biotech Community, discusses volatility and growth in biotech, advocating for a portfolio with a majority of commercial-stage biotechs and a smaller portion of ...